Cargando…
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells
SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum antiviral nucleoside analog. Efficacy is only moderate, and improved treatment strategies are u...
Autores principales: | Nguyenla, Xammy, Wehri, Eddie, Van Dis, Erik, Biering, Scott B., Yamashiro, Livia H., Zhu, Chi, Stroumza, Julien, Dugast-Darzacq, Claire, Graham, Thomas G. W., Wang, Xuanting, Jockusch, Steffen, Tao, Chuanjuan, Chien, Minchen, Xie, Wei, Patel, Dinshaw J., Meyer, Cindy, Garzia, Aitor, Tuschl, Thomas, Russo, James J., Ju, Jingyue, Näär, Anders M., Stanley, Sarah, Schaletzky, Julia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628577/ https://www.ncbi.nlm.nih.gov/pubmed/36323770 http://dx.doi.org/10.1038/s41598-022-21034-5 |
Ejemplares similares
-
SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA
por: Jack, Amanda, et al.
Publicado: (2021) -
Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
por: Wang, Xuanting, et al.
Publicado: (2021) -
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
por: Wang, Xuanting, et al.
Publicado: (2022) -
Open-source RNA extraction and RT-qPCR methods for SARS-CoV-2 detection
por: Graham, Thomas G. W., et al.
Publicado: (2021) -
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
por: Jockusch, Steffen, et al.
Publicado: (2020)